Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of figitumumab plus platinum-etoposide versus platinum-etoposide alone in first-line extensive-stage small cell lung cancer
2009-012857-39Phase 2Completed
- Sponsor
- Pfizer
- Start
- Sep 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of figitumumab in small cell lung cancer (SCLC) (2 arms), sponsored by Pfizer. Primary endpoint: Progression-free survival. Started Sep 2009; status: completed.
02
Drugs
figitumumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2009-012857-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012857-39.